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Like so many before me, I stand here expressing grati-
tude for the opportunity to serve as your president dur-
ing the past nine months. It is a great honor, of course,
but, more than that, it is also the privilege of a career
for one who has never wanted anything more than to
belong to the community of human genetics. I will have
much to say this afternoon about the nature of this com-
munity, both for me as an individual and for us as in-
vestigators, scholars, and educators who have chosen to
spend our professional lives as part of this community.
I have learned many lessons from human genetics and
would like to highlight several of these this afternoon,
as well as to offer you a challenge for our future.
Before I begin on this peaceful afternoon in San Diego,
it is important to reflect on just how much our world
has changed in the last month. A new view of the world
and a new view of the future have been thrust upon us.
We are left to wonder exactly how each of us fits into
this new world and how our work can best go on. We
wonder how our individual and collective efforts in re-
search, education, and the practice of human and med-
ical genetics can best be presented and perceived at a
time of both national and international—and, for some,
very personal—turmoil and tragedy. We are, at the same
time, scientists—with much to contribute by way of un-
derstanding the nature of the human condition—and
individuals—with much to lose because of the nature of
the human condition.
We are not the first generation of scientists to be asked
to meet during the early stages of a war that prom-
ises—or should I say threatens—to occupy our thoughts
and energy for many years to come. And we are not the
first scientists to have to consider thoughtfully how sci-
ence can best be served or can best contribute during a
period of altered political and human priorities. There
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was widespread disruption to science in Europe in the
late 1930s and 1940s, as Europe responded to events at
that time in Germany. Not to increase the anxiety level
among those of you who have flown here from overseas,
but travelers to the Seventh International Congress of
Genetics in Edinburgh in 1939 were torpedoed while
crossing the Atlantic at the outset ofWorldWar II.Many
scientists known to us, including some in this room,
suffered greatly during that period and were asked to
make both scientific concessions and personal sacrifice.
The American Society of Human Genetics played a
role in the aftermath of that war—at least vicariously
through several of its members—by contributing to the
discourse at that time on radiation exposure and social
policy. A number of our members—Jim Neel (ASHG
president in 1953–1954), Jim Crow (ASHG president
in 1963), Bentley Glass (ASHG president in 1967), and
H. J. Muller (the first ASHG president, in 1948–
1949)—were named to the national Committee on Bi-
ological Effects of Atomic Radiation and various
other committees of the National Academy of Sci-
ences, the World Health Organization, and the United
Nations that were formed to address health concerns
about radiation.
Out of these wartime efforts grew a new research fo-
cus: to study the effects of radiation on genes, chro-
mosomes, and the genome. Public health concerns about
the effects of ionizing radiation and chemical mutagens
gave birth to a new generation of research tools to create
novel mutations in model organisms. These efforts led
to the emergence of the national laboratory system—at
Oak Ridge, Berkeley, Livermore, and Los Alamos—each
of which has played a catalytic role in the development
of genetic and, more recently, genomic technologies,
from which the field of human genetics has so clearly
benefited. As one example that is particularly relevant
to us at this meeting, it was studies on the effects of
radiation that led Dan Pinkel and Joe Gray—then at the
Lawrence Livermore Labs in Livermore, California—to
develop fluorescence in situ hybridization methods as a
cytogenetic approach to evaluate chromosome damage.
It is their work that we honor, at this meeting, with the
first Curt Stern Award of this Society. Stern himself
would have been pleased that, in a very real sense, their
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Figure 1 Public opinion on storage of DNA information on
national identification cards. Source: Fabrizio, McLaughlin and
Associates poll of 1,100 adults conducted September 24–26, 2001.
Margin of error 3%.
work is a successor to his own Manhattan District pro-
ject to study genetic effects of radiation at low doses,
testing for the possible effects of exposure to fallout from
nuclear weapons (Stern 1974).
What new areas of science and genetics will emerge
as a result of our new awareness of terrorism? Perhaps
we’ve seen a glimpse of this in only the past few weeks.
Public and government attention to the threats of bio-
logical and chemical warfare—heightened this week
with the discovery of several cases of anthrax infection
in Florida and New York—may lead to increased efforts
to understand how organisms respond to exposure to
such agents. As one example, different strains of mice
exhibit striking differences in susceptibility to lethal tox-
ins, including anthrax. The recent identification of the
gene responsible for differences between anthrax-sus-
ceptible and -resistant strains, by Bill Dietrich and his
colleagues (Watters et al. 2001), received significant at-
tention in the lay press, perhaps more than one might
have anticipated prior to September 11. Are there similar
variants in the human population that might be revealed
in large-scale SNP association studies? Research on
model organisms, one hopes, may provide us with new
insight into the nature of the anthrax response, in order
to develop newer, more effective vaccines.
Or will we be asked to play a more practical role in
preparing us for—or safeguarding us against—future
terrorist attacks? After all, each of our genomic DNAs,
with its unique collection of SNPs, may be the perfect
informational substrate for possible national identifi-
cation cards. Even today, as revealed in a recent survey
(fig. 1), while many Americans are willing to consider
national ID cards, a full 50% of the American public is
unwilling to have DNA information stored on such
cards. This may reflect general ignorance about DNA
uniqueness and what it means or, perhaps, less specific
concern about privacy issues. Clearly, there is a role our
Society could play, both in developing the technology
and databases necessary for such ID cards and in edu-
cating and reassuring the public about the uses of genetic
information.
Another, more somber possibility: there may be a need
for more efficient, high-throughput methods of DNA
genotyping to match and identify personal remains. Our
Society is already engaged in discussions with the Insti-
tute of Justice, a scientific group within the U.S. De-
partment of Justice that is collaborating with the New
York State Forensics Laboratory to develop a plan to
identify personal remains in the aftermath of September
11. Many members of our Society are highly qualified
and, one hopes, will be willing to contribute their ex-
pertise to this effort.
These shifting priorities and the challenges of getting
about business as usual aside, let me particularly wel-
come and acknowledge those of you who have traveled
from overseas to join us at this meeting and who, no
doubt, like those who traveled to the Genetics Congress
in 1939, had to think hard about whether you would
be able to attend this meeting at all. This week, we will
hear presentations from all over the world. It may sur-
prise many of you to know that less than three-quarters
of the presentations here will be made by those from the
Americas. We will hear from scientists from England,
France, Germany, Japan, Italy, Finland, Belgium, Spain,
the Netherlands, Sweden, China, Australia, Denmark,
Austria, Switzerland, Scotland, Israel, Iceland, and Ja-
maica. We’re delighted to have you all with us.
This annual meeting of the American Society of Hu-
man Genetics, then, is in a very real sense an interna-
tional meeting of geneticists and is therefore a celebra-
tion of the unity of men and women of science from
around the globe—scientists of different national ori-
gins, scientists of different personal beliefs, scientists of
different religious backgrounds. Let the clearest and
loudest message of this week be that, at a time when
others would take away freedom of thought and action,
more than 4,400 geneticists from over 20 countries came
together to share new information and to speak their
shared conviction that the open pursuit of knowledge is
far more powerful than the fear of terror.
It is a sad irony—but one worth remembering—that
this is the year of one of our greatest achievements as
human geneticists: the public release of the first draft
sequence of the human genome (International Human
Genome Sequencing Consortium 2001, Venter et al.
2001). This is a time when scientists, philosophers, me-
dia pundits, and politicians alike, from around the
world, all celebrated the single most obvious fact to
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emerge from the human genome sequence: that our ge-
netic similarities are much more profound than our dif-
ferences. It is a sad irony that, in this same year, we are
confronted with the starkest example yet seen in modern
times that there is so much more to learn about at least
some of the differences that mark humankind.
This week, we must attempt to place the work of
human genetics into a larger and broader perspective,
one both scientific and social. Part of my title for this
address alludes to the “storytellers,” those who—both
in science and in the lay press—contribute so much and
so well to our deeper understanding of the human con-
dition. Throughout this address, I will refer to or quote
directly from some of the “stories” that were influential
in determining my own path in genetics or in shaping
my outlook on what is important in science. I am re-
minded of the writings of E. O. Wilson, the Harvard
entomologist and somewhat controversial social Dar-
winist. Some 20 years ago, he published a book, “On
Human Nature,” concerning the biological and genetic
basis for human behavior and the concept of altruistic
genes that are chosen for benefiting society as a whole,
not just the individual (Wilson 1978). In this book, he
wrote, “No species, ours included, possesses a general
purpose beyond the imperatives created by its genetic
history…. To chart our destiny means that we must shift
from automatic control based on our biological prop-
erties to precise steering based on biological knowledge
(pp 2–6).”
Whether one agrees with the basic tenets that Wilson
espouses or not, we are left with our belief that only
greater knowledge and understanding of genetics and its
contributions to the human condition will help us truly
decipher the meaning and potential of the human ge-
nome and lead us to ways of better influencing health
and the state of mankind. That, after all, is our basic
tenet, as stated in the bylaws of this Society (American
Society of Human Genetics Web site):
• to encourage and integrate research, scholarship,
and education in all areas of human genetics,
• to bring into close contact investigators in themany
general fields of research that involve human genetics,
and
• to encourage discourse on the applications of hu-
man genetics as they apply to society at large.
So, who are we in human genetics and where are we
going? As one of the most popular storytellers of all time
said, “it was the best of times, it was the worst of times.”
First, the “best.”
Lesson 1: It Is the Best of Times
There can hardly be a better time to be in genetics. We
have seen dramatic advances over the past few decades
in our understanding, at a molecular and genetic level,
of the role of genes in disease and in our ability to dissect
genetically complex pathways and phenomena that
could hardly be appreciated by generations of scientists
before us. We have explored, at great depth and with
great sophistication, the inner workings of our cells,
chromosomes, and genes, and yet retained enough in-
nocence and enough ignorance to be pleasantly shocked
to find that we have perhaps only a third as many genes
as we thought we had! By following patterns of DNA
polymorphisms in both our mitochondrial and nuclear
genomes, we have learned much in the last two decades
about the evolution of our species and the migrations
and emergence of different human populations around
the globe.
We have seen the dramatic beginnings—but only the
beginnings—of what one might call “translational ge-
netics,” taking fundamental discoveries from the lab-
oratory and applying them to new advances in medicine
in the diagnosis, management, and treatment of disease.
We have brought genetics to medicine, from before con-
ception to the neonatal period and, increasingly, into
adulthood. Even in the aftermath of a genetic tragedy
in the death of a human research subject at the Uni-
versity of Pennsylvania, we have witnessed the very first
demonstrations of clinical efficacy in gene therapy.
And, finally, in the last year, we have seen the un-
veiling of the human genome and the telling of some of
its secrets that shape our genome and its contribution
to human biology and disease. We have dared to pro-
claim that we have seen the future, and it is us. The
“best of times,” indeed.
Lesson 2: Black Boxes
As a group—and even as individuals—we show aston-
ishing breadth in human genetics. What other field can
boast virtuosity over such a dynamic intellectual range?
It is, of course, precisely this breadth that many of us
find so attractive and compelling about our field.Human
genetics offers the opportunity of both medicine and
basic laboratory research. It remains the best of both
worlds. The challenge, however, is to find effective
bridges that connect basic science to medicine. Human
genetics offers a better opportunity to do this effectively
than most fields, but it is still an enormous, and largely
unfulfilled, challenge.
It is the breadth of our field that brings many of us
to this meeting year after year, and it is the breadth of
our field that provides the fodder for discovery in human
genetics. This breadth marks us not only collectively,
but marks even as individuals many of the best scientists
and scholars in our field. Our breadth spans pure basic
scientific inquiry into the formal genetics, as well as
molecular genetics, of bothHomo sapiens and a variety
of versatile model organisms, disease-oriented and pa-
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tient-oriented research into the basis for human disease,
and translational and clinical research at the doorstep
of medical practice. It is a tapestry wide enough to cover
both the most fundamental advances in basic science
and the most potentially meaningful applications in
medicine.
It is this breadth that invites and enriches the con-
ceptual leaps that any field needs to make real progress.
I refer not to progress of the sort as one travels down
a well-marked path, with reasonably predicable out-
comes and advances. Rather, it is the discovery of what
I’ve called in my title “black boxes.” These are the to-
tally unforeseen and unpredictable discoveries that
come only from a willingness to wander—at least in-
tellectually—well off the path in search of explanations
for the unexplained; in search of broader implications
for what may, at first, seem like an incidental obser-
vation; or in search of new tools needed to chip away
at or peer into the black box of uncertainty that sur-
rounds so much of genetics. It is these conceptual and
technical leaps that not only open doors but point to
the existence of doors where there were none.
Let’s look at some examples of what I mean.We could
go back to Sir Archibald Garrod, the father of inborn
errors of metabolism, who nearly 100 years ago first
articulated the significance of those rare individuals
whose, in his words, “alternative course of metabo-
lism…must be looked upon as somewhat inferior to the
ordinary plan” (Garrod 1902). His notion of “chemical
individuality” provided a conceptual understanding in
humans—for the first time in any organism—of themet-
abolic and biochemical consequences of genetic defi-
ciency in individual genes, a lasting concept with pro-
found implications for both biology and medicine.
Or we could look to Al Knudson’s statistical evalu-
ation of epidemiological data in the rare childhood tu-
mor retinoblastoma and his careful articulation of the
two-hit hypothesis of cancer that has served the fields
of human genetics and cancer molecular biology so well
for the past 30 years (Knudson 1971). Or to the the-
oretical enunciation of the power of restriction frag-
ment length polymorphisms and linkage maps by Bot-
stein, Skolnick, White, and Davis, published in The
American Journal of Human Genetics in 1980 (Botstein
et al. 1980). Or the demonstration by Kan and Dozy
of the practical value of such RFLPs for studying the
evolution and diagnosis of sickle-cell anemia (Kan and
Dozy 1978).
This is a particularly good example to explore, be-
cause it not only underscores the dizzying speed of con-
verting basic discovery in human genetics to clinical
benefit but also proves the old maxim that chance favors
the prepared or, in this case, the broadly educated mind.
First recognizing and then cracking this particular black
box required mindful physician-scientists, driven by a
clinical need and aware of the theoretical value of poly-
morphisms in prenatal diagnosis. This concept wasn’t
new; after all, it was proposed initially by Haldane in
the context of protein polymorphisms (Haldane and
Smith 1947). But it took another 30 years to develop
the theory more formally and generally in the context
of DNA polymorphisms, building upon the discovery
of human DNA polymorphisms in 1978 by two groups.
One was the chance observation of a single nucleotide
difference between independent genomic clones by
Lawn and Maniatis when they first cloned the human
b-globin gene (Lawn et al. 1978); little was made of
this observation or of its potential human genetic im-
plications. The second discovery, however, was Kan and
Dozy’s careful elucidation in the same year of a different
RFLP downstream of the sickle-cell mutation (Kan and
Dozy 1978). This paper was a model of prescient think-
ing and provided a clear outline for much of molecular
genetic analysis in our field during the 1980’s. It took
the breadth of the field—encompassing medicine, for-
mal genetics, and molecular genetics—to capture the
true significance and promise of this particular concep-
tual breakthrough.
For those of you students whose eyes are rolling up
because you’ve never heard of some of these people and
can’t believe I’m prattling on about events way back in
the 1970s (much less the 1940s), let me assure you that
there are more-recent examples too. There was Sir Alec
Jeffreys, who discovered, in 1985, the existence of
highly polymorphic minisatellite DNA loci in the hu-
man genome and gave birth to an entire new industry
based on DNA fingerprinting (Jeffreys et al. 1985).
There are any number of clinical geneticists who dem-
onstrate repeatedly the value of the rare, and sometimes
unique, patient for illuminating black boxes. One of my
favorite examples of this involves Bonnie Pagon and
Uta Francke (ASHG president in 1999), who under-
stood implicitly the significance of an unusual patient,
B.B., who presented with four normally distinct X-
linked diseases simultaneously (Francke et al. 1985). It
was this patient’s deleted X chromosome and DNA that
led to the elucidation and eventual positional cloning
of genes for all four of these disorders (chronic gran-
ulomatous disease, retinitis pigmentosum, McLeod syn-
drome, and Duchenne muscular dystrophy).
There were the cytogenetics and clinical genetics com-
munities, starting with David Ledbetter, whose careful
persistence to follow-up on chromosome 15s that
looked just a little bit shorter under the microscope
revealed the cytogenetically tiny deletion that marks
Prader-Willi syndrome. It was this finding, followed by
Merlin Butler’s insight that virtually all of the dele-
tions were paternally derived, that laid the groundwork
for the eventual documentation by Rob Nicholls of im-
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printing as a black box concept in human genetics
(Nicholls et al. 1989).
There was Art Beaudet (ASHG president in 1998),
who recognized an unusual female patient with cystic
fibrosis whose father appeared not to be a carrier.
Rather than assume nonpaternity, which, no doubt,
many would have done, his group demonstrated that
the girl had inherited two full copies of her mother’s
chromosome 7 and no copies of her father’s chromo-
some 7 (Spence et al. 1988). This was the first fully
documented case of uniparental disomy in humans—a
black box, at the time, if ever there was one!
There was Haig Kazazian, whose discovery of an L1
repeat element inserted into the factor VIII gene in two
cases of hemophilia A (Kazazian et al. 1988) established
the relevance of this class of repeats in medical genetics
and uncovered the surprising degree of dynamic move-
ment of L1 elements in our genome.
There was Carolyn Brown, then a postdoctoral fellow
in my lab, who persisted in trying to explain an obser-
vation that had no obvious explanation: an X-linked
gene that seemed to be expressed only in females, not
in males (Brown et al. 1991). Her persistence (verymuch
in the face of my initial skepticism, I must confess) led
to the description of the XIST gene, now known to play
a pivotal role in X chromosome inactivation.
And, as a final example, there was Stephanie Sher-
man—also still a trainee at the time—who outlined
what became widely known as the “Sherman paradox”
(the observation that the penetrance of fragile X mental
retardation differed in different carriers within the same
pedigree and appeared to depend on one’s position in
the pedigree [Sherman et al. 1985]). This concept, de-
rived (it should be stressed) only from formal genetic
considerations, defied explanation until the gene was
cloned a few years later and one of the most famous of
the black boxes to emerge from human genetics was
uncovered—namely, trinucleotide repeat expansion.
Who in the next generation of trainees, in this age of
genomic reductionism—where everything, it seems, has
to have an explanation embedded in our genome se-
quence—who will propose the next new genetic concept
with no obvious precedent or molecular explanation?
What marks each of these discoveries is the imagi-
nation and intellectual courage that it takes to stray off
the path and look for black boxes. Real progress—in
this or any field—requires that we don’t just walk
through open doors; we must be open to the possibility
that there are doors we haven’t even seen yet and be
open to the data that first hint at the existence of those
doors. I like black boxes, because they challenge one’s
thinking to the extreme and invite us to muse about
what mind-boggling, possibly crazy, probably even
wrong in detail, explanations could conceivably explain
the data. I like black boxes, because you can draw some-
times wildly speculative models, and no one can look
up the answer in the back of the book and tell you are
wrong. No one can look to other systems or precedents
and tell you that you must be crazy. Youmight be crazy,
of course, but, then again, you just might be right. My
delight with black boxes probably shouldn’t come as a
surprise. After all, I’ve spent much of the last 20 years
ignoring proteins and instead chasing after repetitive,
so-called “junk” DNA and noncoding transcripts in
our genome. Those were—and to a large extent still
are—black boxes.
Lesson 3: When Nothing Else Works, Stop and Think
The early decades of human genetics were full of such
musings. After all, today’s younger scientists might has-
ten to point out, there wasn’t much else to do! There
were no cloned genes and databases of genome sequence.
There weren’t transgenic mice or yeast models to test
critical predictions of hypotheses. There weren’t fancy
confocal microscopes or deconvolution software to pro-
vide high-resolution images in three dimensions or in
living cells. Without a catalogue of enzymes and genes,
one had the freedom to infer the existence of new ac-
tivities and the role they might play in metabolism or
development. Often, of course, as I’ve just illustrated,
such insights came from a collection of patients or even
that one unique patient whose phenotype begged for an
explanation. Absent complete data, one had to rely on
one’s cunning and, well, just plain thinking, to milk all
that one could out of limiting amounts of clinical or
laboratory data. How different the challenge is now,
when we are, at times, inundated with mountains of
data, and the task is to sort through them to find the
most cogent and the most meaningful. It takes great
intellectual discipline to put your pipette down and just
think about the data. The best and most impactful sci-
entists do this regularly.
In those premolecular and pregenome years in human
genetics, there were often just the hypotheses. Some of
them were truly creative and mind-stretching exercises,
free from the confining scaffold of well-understood mo-
lecular, cellular, and genomic principles that now en-
lighten us all but tend to constrict our freedom of
movement intellectually. In the 1960s and 1970s es-
pecially, the literature was full of wonderful genetic
models to explain how things might work. They greatly
advanced our thinking and prepared the field to accept
the notion of a totally novel and unanticipated mech-
anism once the data were advanced enough to dem-
onstrate it convincingly.
Many of the black boxes that I’ve discussed are now
well known (and, in some cases, even well understood),
and it may be difficult for some trainees in the audience
to consider a day when these concepts were not a fully
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established part of human genetics. It is a sign of their
significance, however, that each of these formerly-black
boxes is now so firmly rooted in our field. These dis-
coveries, and so many others like them, opened new
doors where there were none before and where there is
now an open passage for exploration and further dis-
covery. The impact of such discoveries goes well beyond
either basic science or clinical observation; their hall-
mark is that their significance blends the basic science
of genetics with the keen eye and practical imperative
of human and medical genetics.
Lesson 4: The View from Outside the Tent
So, what’s wrong with this picture? Why do I not share
the enthusiasm and optimism of so many of my col-
leagues? As I’ve just illustrated, my sense of concern is
certainly not for the field of human genetics in general
or for its capacity to contribute in increasingly significant
ways to our deeper understanding of human biology or
medicine. Rather, my concern is for the challenges that
await this organization—the American Society of Hu-
man Genetics. My concern is for its vitality, for its ability
to continue to grow and thrive and to assume or main-
tain a leadership position in applying genetics to human
biology and medicine. In a sense, our successes—both
scientific and political—in bringing human and medical
genetics into the limelight and in proving that we are
indeed “relevant” threaten to be our downfall.
The state of our field and the prospects for its future
are stronger than ever, but the state of our Society, I
fear, is less certain. Let me explain.
My concern is that the view from inside the tent and
that from outside the tent are very different. The single
clearest manifestation of what it means to be a member
of this Society, of what it means to be a human geneticist
as any of us would define it, is our yearly attendance
at this meeting. I have been attending this meeting every
year since 1975, my first meeting, when I presented a
paper based on my work as an undergraduate with the
late Sam Latt. It was he who taught me that this was
the one meeting that you pointed your work towards
each year. I cannot imagine a fall going by without
attending this meeting and without members of my lab-
oratory presenting their work for consideration and
evaluation by this community. I know there are many
of you who share this conviction and have attended far
more meetings than I have! We are truly a Society of
many generations, and this is one of the great successes
of this community.
My concern isn’t about those of us who are here. My
concern is about those who are not here, those who
consider themselves human geneticists—or at least bi-
ologists or physicians interested in human genetics—but
who do not consider this meeting to be either important
or exciting enough for them to attend.
My concern is twofold. First, with human genetics
and genomics finding itself in so many venues, the temp-
tations, if you will, for the next generation are great.
Students and other trainees show, in many cases, an
indifference to this Society and its meeting. The breadth
of human genetics—precisely what I just described as
being our strength and defining quality—gives us an air
of being a bit (how shall I say this?) “old-fashioned”
and “stuffy.” Even among those of us on the inside, we
have argued for years about whether our meeting was
getting to be “too molecular” or “too clinical” and
whether we were adequately and equally serving all of
the various constituencies that make up human genetics.
But, for all our internal debates, we should acknowledge
that many of those on the outside have already voted
with their feet. There are just too many alterna-
tives—genome meetings, Gordon Conferences or Key-
stone Symposia in specialty areas, or meetings of other
scholarly societies—that are perceived to be more ex-
citing and somehow more modern and relevant to them
than this one.
My second concern is that those outside of the tent
mean something very different than we do when they
refer to human genetics or when they talk about the
impact of genetics on the future of medicine. When
many of them talk in this way, what they really mean
is the molecular biology of human genes or perhaps
“functional genomics,” to use the most common mod-
ern buzz phrase. Their perspective may be from the
standpoint of physiology or cardiology or neurology,
rather than from a strong foundation in human genetics.
However, this concern of mine can also be stated as
an opportunity and a challenge. We should broaden our
perspective and be inclusive. It is only by doing so that
we will be able to demonstrate our vitality and deliver
on the great promise that our field holds. Not only
should we openly welcome others to our field, but we
must work harder to ensure that they feel welcome in-
side our tent. As stewards of the field of human genetics,
we have much to lose if they don’t. We run the risk
that—in contrast to what I said earlier—we have seen
the future, and it is not us! We run the risk—a very real
one, in my opinion—that we will wake up and find
ourselves on the sidelines, not at center court.
So what’s the evidence? For starters, let’s look at our
own membership numbers (fig. 2). To be sure, our mem-
bership has increased every year for decades, and we
can boast of a 20% increase over the past five years
and a 10% increase in the last year alone. But compare
this with the period from 1991 to 1996, when mem-
bership grew by almost 40%. And put this in the context
of our field. Human genetics is supposed to be the hot-
test ticket in town, if you believe the press releases! We
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Figure 2 Membership trends in the American Society of Hu-
man Genetics, 1986–2001.
Figure 3 Comparison of membership trends in the American
Society of Human Genetics, the American Society for Cell Biology,
and the Society for Neuroscience.
have enjoyed spectacular successes, with the promise of
even more spectacular ones—and ones of more general
interest and significance—to come.
So where are all the converts? Attendance growth at
this meeting during the past decade—during this period
of increasing profile, various Time and Newsweek
covers, and even the Human Genome Project—has ac-
tually been fairly modest. Over the past nine years, the
average growth rate in attendance at this meeting is only
about 4% per year. Not bad, but hardly what one might
expect for the hottest field in the business. The ines-
capable conclusion is that the converts are outside the
tent, not inside!
Where did everyone go? Compare our numbers with
those in the Society for Neuroscience (fig. 3). Here,
membership has exploded, more than doubling since
1990. It is a similar story for the American Society for
Cell Biology. The combined membership of these two
groups is some five times that of our Society. Want to
go to a meeting with lots of human genetics talks? Check
out the abstract book for the Neuroscience meeting! To
cite another example—in another area that overlaps hu-
man genetics—consider gene therapy. The American So-
ciety of Gene Therapy is only five years old, having been
established in 1996. But its membership has already
increased to about 3,000 members during that time. (By
comparison, it took us 35 years to get to that level!)
Does this mean that neuroscience, cell biology, and gene
therapy are more exciting than human genetics? No,
not at all. But it does mean that we have some work
to do.
Let’s consider next the Human Genome Project and
the annual Cold Spring Harbor meeting on the genome.
The overwhelming success of that meeting, which began
in 1988, can, I believe, be attributed, in no small part,
to actions (or inaction) on our part. After all, it was the
conclusion of members of this Society that the Human
Genome Project being proposed in the late 1980s was
largely outside the purview of the American Society of
Human Genetics. Support for the project from this So-
ciety derived largely from our interest in the medical
implications of the project, rather than our participation
in the research per se at the interface of human genetics
and genomics. In retrospect, we should have recognized
that we couldn’t count on one without first investing in
the other.
Consider this statement from the report of our Hu-
man Genome Committee (ASHG Human Genome
Committee Report 1991): “The Human Genome Pro-
ject is…of particular interest to the ASHG.” So far so
good. But the reason? Because “ASHG has within its
membership the vast majority of American and Cana-
dian health care personnel involved in the development
and delivery of genetic services to the North American
public.” The Committee formed three working groups
at that time to address health care issues, educational
issues, and legal, ethical, and social issues related to the
genome project. But missing was a working group on
genome science! Clearly the science of the project itself
was not perceived to be in our purview. It was pushed
outside our tent, and the Cold Spring Harbor meeting
and many other genome meetings and organizations
sprang up to capture the excitement and the science of
human genome research. I believe we are now paying
a price for those decisions. We needed a bigger tent.
I do not intend to be overly critical of the Committee
and its deliberations. It was, after all, the considered
opinion of leaders in our Society at that time, and the
process followed was deliberate and thoroughly dem-
ocratic and driven by the membership. I was on the
Program Committee then, and we wrestled diligently
and thoughtfully with the extent to which genomics
belonged at this meeting. In our efforts to preserve the
special flavor of our Society and its meeting, we un-
wittingly contributed to one of the problems that I be-
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lieve we are now confronting. Much of the commonly
perceived excitement and vitality is on the outside.
There are no easy answers, and hindsight is, of course,
20:20. But I believe we made the wrong choice 10 years
ago. Should we have then—or should we now—
consider a more expansive Society and a different type
of meeting that would enlarge the tent? Are we content
with a meeting of the current size and diversity? Would
our field be better served or would it be hurt if we were
the size of, say, the Neuroscience meeting? And, if it
would be better served, how do we do enlarge the tent
while preserving those aspects of this meeting and our
Society that are central to who we are? Without pre-
judging the answers, I believe these are questions that
we must debate and consider.
Lesson 5: We Need a Bigger Tent
To begin this dialogue, I would argue that not only do
we need a bigger tent but we need to change how we
present ourselves, how we state our interests, and what
we offer to scientists who are currently in fields that we
now indicate are largely outside our purview. Simply put,
if we want to attract a broader audience with diverse
but legitimate interests in genetics and genomics, partic-
ularly as they apply to the future of medicine, then we
will need to change our body language. While we meet
annually to celebrate the advances in our field—
and they are substantial ones of which we should be
proud—there is an entire world going on outside our
tent. Our voice is loud and resonant inside the tent, but
we are less effective at being heard outside.
I believe that we must consider strategies to throw
open the doors and invite the others in. We must better
articulate what human genetics is, and we must identify
a group of thought leaders who can argue effectively
for “human genetics” as we mean it, integrated with
“human genetics” in a broader sense as they mean it.
I refer again to our by-laws and to one of the objectives
of our Society: “to bring into close contact investigators
in the many general fields of research that involve hu-
man genetics.” If we believe our own words, then we
must expand our attractiveness to those in other fields
and other areas of science and technology. Everyone
nowadays is doing genetics! This is good news, and we
need to find a way to welcome them into the tent.
Let’s consider some examples of who I mean. As suc-
cessful as we are in attracting academic human genet-
icists from around the world, we have done an ineffec-
tive job, at best, of attracting geneticists from the
for-profit sector. This is a meeting for the open presen-
tation and discussion of data, and we should openly
welcome scientists from the pharmaceutical and bio-
technology industries, as well as those from genomics
and diagnostics companies, to participate fully. Make
no mistake—“fully” means “openly.” They must be
willing to present their data, just like the rest of us, and
hold it up to scrutiny and discussion. Some do just that.
But it is a fact that only 3% of the platform presenta-
tions at the meeting this week are primarily from com-
panies. You can be sure that a much, much larger vol-
ume of human genetics research is going on in
companies that is not presented here. Many of those
scientists participate fully in other meetings, such as the
American Society of Gene Therapy meeting and a va-
riety of genomics meetings. Somehow, we have failed
to deliver an effective invitation to the for-profit sector,
or we have failed to offer an attractivemessage for them.
They are very much amajor part of the future of genetics
in medicine, but they are outside our tent. I believe this
must change.
There are other groups whomwemust engage as well,
outside of our usual audience. Bioinformatics is one
such field that is just beginning in full force in academic
circles but that is currently more closely affiliated with
genomics meetings than with this meeting. There are
emerging technologies that are appropriate to be rep-
resented here as well: technologies, for example, to de-
velop better gene chips for population screening or tech-
nologies in proteomics that we are just beginning to
hear about at this meeting. This science is tremendously
exciting and certainly relevant to us. But they are cur-
rently outside the tent. I believe this must change.
And what about model organisms? Even Gregor
Mendel and Charles Darwin worked with model or-
ganisms! There are spectacular advances in understand-
ing the genetics of mice, rats, flies, worms, zebrafish,
pufferfish, and even plants. All of this is highly relevant
to human genetics and has enormous implications for
human biology and medicine. However, we only oc-
casionally hear of this work at these meetings. For the
most part, they are currently outside the tent. I believe
this must change.
I believe all this must change if this meeting and this
Society are to retain our vitality, because it is the leaders
of many of these companies and these other fields who
will increasingly drive the revolution in medicine and
in biology that we hope to be part of. I believe it does
little good for us to meet by ourselves and make grand
pronouncements about the future of genetics and gen-
omics in medicine, while we ignore—or react belatedly
to—the world around us. There is terrific science all
around us, being presented at a variety of other venues
by scientists and physicians who believe deeply in the
impact of genetics on what they do and yet have little
reason to think about or know about what goes on here.
Make no mistake: I think it’s evident that the vast
majority of those engaged in genetics research relevant
to medicine will not be those we might consider to be
“card-carrying” human geneticists. And I think it’s ev-
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ident that the vast majority of those who will practice
genetics in medicine will not be board-certified medical
geneticists. We had better get used to it. All the evidence
argues that the revolution has already started and that
we have yet to find an effective voice. We can do better.
But to do this, our Society, its members, and its lead-
ership will have to address what kind of Society we
want to be, both now and 10 years from now.
Lesson 6: Two Cultures
To be sure, an alliance between academic societies and
the for-profit sector is potentially an uncomfortable one.
After all, the two cultures are founded on very different
principles and beliefs. My thinking in this area has been
shaped by two very different books. The first is perhaps
the best novel ever written about the research enterprise
and the differences between medical scholars, basic sci-
entists, and those in the pharmaceutical industry—
Arrowsmith by Sinclair Lewis (Lewis 1924). I first read
this book as a high school student, and it was a source
of inspiration that legitimized my interest in laboratory
research as a career goal. The second book is a thor-
oughly informative and convincing discourse on Amer-
ica’s universities, called Academic Duty,written by Don-
ald Kennedy, former president of Stanford University
and now editor-in-chief of Science (Kennedy 1997). In
it, he explores the different pressures on universities and
their faculty, viewed particularly against a background
of intensive research activity. It focuses, as the title sug-
gests, on what it means to be part of the Academy, what
its freedoms are and what its responsibilities are. This
should be required reading for every junior faculty mem-
ber, at the time they take up their first job at a university,
and again for every senior faculty member, at the time
they consider or take up leadership or administrative
roles.
All institutions of higher learning have as their pri-
mary mission one thing: to educate students. The bio-
medical research enterprise, substantial as it is, partic-
ularly at the top level of research-intensive universities
and medical schools, is nonetheless secondary in the
eyes of the public and of the boards of trustees who are
charged with oversight responsibility for the academic
trust. A uniquely academic solution to the potential con-
flicts between research and education is part of what
distinguishes the research cultures of a university and
thatof a for-profit company. The union between original
research and research training—a tradition borrowed
from the German university system and imported to the
United States over 100 years ago—puts substantial em-
phasis on training young academics to take their
places in the nation’s universities. The belief behind
the university culture, as Kennedy writes, is that “en-
larging and disseminating knowledge are equally im-
portant activities and that each is done better when both
are done in the same place by the same people.” (Ken-
nedy 1997, p. 28)
Contrast this with the experience, portrayed in Ar-
rowsmith, of Max Gottlieb, a former medical school
professor who, with some discomfort, moves his re-
search to a Pittsburgh pharmaceutical firm. The poten-
tial conflicts inherent in attempting to perform basic
research in such a setting are evident throughout this
somewhat cynical tale. The cultural differences become
apparent when the company’s CEO confronts Gottlieb,
the basic scientist. As the CEO reminds him, “Person-
ally, I should like nothing so much as to spendmywhole
life in just producing one priceless scientific discovery….
But we have our duty toward the stockholders.” (Lewis
1924, p. 135)
So, no matter what the motivation of individual
scientists, we can’t overlook that the primary mission
of a university and the primary mission of a com-
mercial enterprise are different. But within that con-
text, meetings such as this can provide a common
meeting ground, where scientists with a shared in-
terest in the science can openly present their findings
and discuss their implications.
We have our own Gottliebs of course. Over the years,
a number of high-profile human geneticists have left
academia, temporarily or permanently, to move to in-
dustry. But, rather than “vote them off the island” (to
use a current phrase), we need to encourage their con-
tinued participation in our Society and our meeting and
to ensure that we offer a meeting that meets their needs
as well as our own. There is a gulf to bridge between
universities and industry, and academic societies like
ours can play a key role in this. This is not as impossible
as it may seem. We are, after all, not the first discipline
to have considered the value and importance of doing
this. Chemists and engineers, to name two, have suc-
cessfully bridged the gulf. So have pharmacologists and
endocrinologists. The genomics community has been
much more open to this and successful at it than has
the genetics community. But as the ranks of those in
industry who are interested in human genetics increase,
we have a lot to gain by finding ways of continuing to
break bread with them. And we have a lot to lose if we
don’t.
There is another reason to consider enlarging our
tent. Genetics (and certainly genomics) is now “big sci-
ence.” Even Kennedy, himself a former University pres-
ident, acknowledges that there is widespread skepticism
“about the university’s ability to reorganize, to marshal
the diverse talents necessary to approach complex prob-
lems of large scale” (Kennedy 1977, p. 278). To be sure,
human genetics—with its breadth of focus on basic sci-
ence, practical applications to medicine, and increas-
ingly important social policy implications—is one of
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those “complex problems of large scale” that Kennedy
refers to. To successfully tackle such a problem almost
certainly will require input of energy and resources from
a diverse set of organized units—universities, to be sure,
but also independent research organizations, in both the
academic and commercial worlds.
These are two different cultures, and the gulf between
them needs to be bridged. This is where the American
Society of Human Genetics can come in, if we are will-
ing. None of this will happen without an attitudinal
change, and our Society can help to catalyze this as an
agent of change.
Lesson 7: Mentoring
In addition to the open exchange of information, one of
the values that we must protect at all costs is mentoring
our young trainees and ensuring the cultural transmis-
sion of our field from one generation to the next. This
is very much a part of who we are as individual faculty
members and scientists, but this is also one of the de-
fining qualities of this Society and its annual meeting.
Kennedy’s book provides a careful analysis of what
is needed for proper mentoring, together with the po-
tential pitfalls and traps that sloppy or inattentive, or
just plain misguided, mentors can fall into, mostly to
the detriment of their trainees. As Kennedy notes, “The
student’s experience depends heavily on the good will
and conscientiousness of a single mentor. It requires
total immersion in a demanding scholarly discipline….
The experience is often lonely and may be profoundly
alienating. Yet at its best, with an inspiring and com-
passionate mentor, it can be positive and even trans-
forming.” (Kennedy 1977, p. 45)
I can attest to that. I was fortunate to have been
mentored by passionate practitioners of the transform-
ing quality of good mentoring. In keeping with Ken-
nedy’s comments, let me single out my experience as a
graduate student under Leon Rosenberg in the then De-
partment of Human Genetics at Yale in the late 1970s.
My experiences with Lee, usually one-on-one early in
the morning or on weekends, were almost uniformly
uplifting and ultimately transforming. Like all effective
mentors, he knew which buttons to push and when to
push them. I cannot adequately express the debt I feel
to him. Whatever I may have accomplished in this field,
either as a scientist or as a member of this Society, I
owe to him.
The mentoring experience in science takes on a sin-
gular, one-on-one quality, much like the relationship
between master and apprentice. Those of you who are
or who have been graduate students will recognize the
true ring behind the following excerpts from popular
accounts of this relationship.
First, Max Gottlieb again, when he was still a medical
school professor, talking to Martin Arrowsmith asMar-
tin begins his years of research training: “There are two
kinds of students the gods give me. One kind they dump
on me like a bushel of potatoes. I do not like potatoes,
and the potatoes they do not ever seem to have great
affection for me…. The other kind—they are very
few!—they seem for some reason…to wish a little bit
to become scientists…. Of the potatoes, I demand noth-
ing; of the…ones like you, who think I could teach them
something, I demand everything” (Lewis 1924, p. 15).
An absolutely wonderful book that tells this story
well from the standpoint of a classic genetics story is
Mr. Darwin’s Shooter (McDonald 1998), an account of
Darwin’s travels on the HMS Beagle, leading up to his
publishing The Origin of Species. The tale is told from
the vantage point of Syms Covington, a historically ac-
curate figure who was at Darwin’s side from 1832 to
1838 on his voyage. Covington became Darwin’s
“shooter,” the one responsible for shooting and then
collecting various specimens, including the famous
finches, for transport on the Beagle back to England.
Syms is, at first, a bit of a misfit, using the wrong
powder or miscalculating the amount of shot to use for
a particular target and often blasting Darwin’s hoped
for specimens to bits. But, like any first-year graduate
student, he soon begins to get the hang of it and even
to enjoy it. Covington works hard and eventually, as
we would say, turns the corner. “He [finally] thought it
advantageous to think like his master,…making con-
nections and not just reporting facts, but whatever facts
might seem to be important. How full of himself he
was, all spunk and spittle.” (McDonald 1998, p. 245)
We know the ending of this tale, of course. “Recall,
thought Covington, [Darwin] and his catechism: ‘Look
for variations among common types’” (McDonald
1998, p. 260). Covington—and the world—is trans-
formed. “Thus did ‘what is life?’ become a question in
the mind of an ordinary young man” (McDonald 1998,
p. 301).
And lastly, a bit lighter touch. Carl Djerassi, the
award-winning Stanford chemist who invented the first
oral contraceptive, has written a delightful little novel,
called Cantor’s Dilemma, about the ethics, politics, and
practice of big-time research, starring a professor and
his beleaguered trainee. (There are great lessons here
about how not to mentor and about the potential con-
flicts of interest that can weigh heavily on the mentor-
trainee relationship. This book also illustrates why read-
ers of the popular press have such a distorted view of
what we do for a living!) Professor Cantor attempts to
explain his work habits to a nonscience friend of his,
Paula:
“I would have called, but the last few weeks have
been frantic. I’ve been working every day, and most
evenings, in the lab….”
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“I thought that you had a group of devoted slaves at
your beck and call.”
“Paula, we call them…coworkers” (Djerassi 1989, p.
100).
Lesson 8: Academic Duty
Life in human genetics is not all research and mentoring,
of course. For most of us, there are committee meetings,
grants to write or review, papers to review—all contri-
butions to the academic way of life that most of us value
so much. This is the “stuff of academic duty,” as Ken-
nedy calls it. No university and no academic Society like
ours can survive without it. And yet, I confess, I am
concerned that we are dividing into two groups of mem-
bers. First, there are those who were trained to meet this
duty and who do so willingly (for the most part), freely
expending sometimes enormous amounts of time and
energy to ensure that the system works and thrives.
These are those who join study sections, who join com-
mittees at their universities or in various genetics or-
ganizations, who edit or review for our scientific jour-
nals, who volunteer to run courses.
But there are also those who, armed with the excuse
that they are too busy, simply say no. My concern is
that this second response seems increasingly to be con-
sidered a legitimate survival tactic, if you will, to protect
enough time for one’s research. To the contrary, in my
opinion there is nothing legitimate about this, and it
threatens the fabric on which our academic life is based.
In my view, it is one of our jobs in the business of
biomedical research, especially that which is based in
academia, to ensure that there is an adequate supply of
those whose sense of civic consciousness brings them to
commit their best talents to the overall good. Maybe
I’ve come full circle to return to the concept of altruistic
genes, of which I spoke at the outset of this address!
This may seem to be an overly harsh assessment, but
I reserve my greatest respect for those who have the
strongest sense of academic duty. And, happily, there
are many of them—many of you—in this room. We
must encourage and reward those who are the most
generous with their time, and we must ensure that we
imbue in the next generation this same sense of citizen-
ship. “Part of academic duty is the practice of civility
in scholarly discourse—through which we may, by ex-
ample, encourage the kinds of attitudes and behaviors
we see among our most generous colleagues” (Kennedy,
p. 184). The community depends on it.
Lesson 9: The Community
Let me conclude with a few thoughts about this com-
munity. I was trained in human genetics, have spent my
entire professional life in human genetics, and have never
wanted anything other than to be a part of this com-
munity. You have done me great honor by electing me to
be your president, as you have done to those before me.
My time in this community has been enriched enor-
mously by “the kinds of attitudes and behaviors we see
among our most generous colleagues.” I’ve already
mentioned my mentors. But I’m equally indebted to a
number of other colleagues who were unusually gen-
erous in helping me to find my voice. Sometimes, it was
just a small thing, a gently encouraging word here or
there, an invitation to dinner when in a strange city,
someone taking or returning a phone call when they
didn’t have to, a “softball” question lobbed up to a
nervous student giving his first talk, or a chance en-
counter that elevates the scientific soul and instills a
sense of belonging to this community. Random acts of
genetic kindness.
So my final plea is that we each spend a little extra
energy to do what we should do best in this commu-
nity—to encourage and welcome new members. This is
especially true among the younger set. We should work
hard to ensure that they have the opportunities to find
their own voices in this community. This will be good
for them, of course, but it is also good for us, as it will
ensure the survival of our discipline. This Society and
this meeting have always provided for many of those
rites of passage that are critical to a young member
finding his or her voice: reviewing an article for The
American Journal of Human Genetics; being asked to
moderate a session at our annual meeting; being invited
by Victor McKusick to give a lecture at the Bar Harbor
Short Course; or being asked to write a chapter for what
used to be simply “Stanbury” or now “Scriver” (offi-
cially called The Metabolic and Molecular Bases of In-
herited Disease). These were and are all big steps in the
development of a professional career in human genetics.
Those of us at the senior end of things have benefited
enormously from being a part of this community; we
should do our best to share those benefits with those
just warming up their voices, still waiting in the wings.
This year’s meeting will be a bit unusual for us all,
because of world events that have preoccupied each of
us over the course of the last month. The schedule of
the meeting itself has been subject to a number of last-
minute changes, to accommodate changes in plans by
scheduled speakers. The schedule will have, as a result,
a few holes here and there, when there will be a 15-
minute gap because of a missing speaker. I would sug-
gest that, during those breaks, you turn to a young
colleague, introduce yourself, ask who they are and
what they work on, ask what they want to do with their
careers, tell them why human genetics is such a won-
derful field to be part of, and welcome them to our
community.
Ours is a community of personal and professional
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generosity, notable achievement and great promise. As
a field and as a Society, we have worked hard to put
ourselves at the center of an immensely exciting revo-
lution in thought, scientific understanding, and practical
application. We should ensure that our community re-
mains at the center. Let’s get on with it.
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